Abstract: A gaming system has a display (54). A player hand selector (623) is arranged to select a plurality of symbols to form a player hand for display on the display (54). A symbol selector (561) is operable by a player to select one or more symbols of the player hand. A hand display modifier (622) is arranged to modify the display of at least part of the player hand so that the size of each selected symbol is different to each non-selected symbol to assist a player to distinguish selected and non-selected symbols within the player hand.

Abstract: A method of displaying performance data in a gaming system, the method comprising: deriving at least one performance measure from at least one performance parameter of each of a plurality of gaming terminals; graphically representing the performance measure on a display; and displaying a representation of the performance of each gaming terminal relative to the graphically represented performance measure, the representation based on the at least one performance parameter of the gaming terminal.

Abstract: A protective floor film includes a base film layer and a U.V. cured wear layer disposed on the base film layer. The wear layer has a thickness in a range of 2 to 25 micrometers. Methods of making protective floor film and methods of protecting a floor are also disclosed.

Abstract: Compositions, and methods of use thereof, are provided for the prevention, treatment or alleviation of symptoms of hearing are provided. The methods employ nicergoline, MMDL or MDL as the sole active pharmaceutical agent or a combination of nicergoline, MMDL or MDL and another pharmaceutical agent, such as an antioxidant, a NMDA antagonist, an SSRI or a combined SSRI/NMDA antagonist agent. The method involves the use of nicergoline, MMDL or MDL alone or in combination with another API to prevent, treat or ameliorate one or more symptoms of hearing loss.

Abstract: Compositions, and methods of use thereof, are provided for the prevention, treatment or alleviation of symptoms of hearing are provided. Embodiments of the methods employ zonisamide as the sole active pharmaceutical agent or a combination of zonisamide and another pharmaceutical agent, such as an antioxidant, a NMDA antagonist, an SSRI or a combined SSRI/NMDA antagonist agent. Other embodiments of the method involve the use of zonisamide alone or in combination with another API to prevent, treat or ameliorate one or more symptoms of hearing loss. Hearing disorders treatable with the invention include noise-induced hearing loss, drug-induced hearing loss, central auditory hearing disorder (CAPD), tinnitus and presbyacusis.

Abstract: A speaker that includes a pair of spaced-apart, in-plane mounted drivers connected in series to a network for applying the appropriate frequency component of the electrical input drive signal to each of the drivers is disclosed. A frequency dependent shunting network, such as a low pass filter, is applied to one of the drivers so as to gradually mute the one driver as a desired frequency is approached. The result is an aesthetically pleasing speaker that has dual in-plane drivers and that produces superior sound quality throughout the entire frequency range of the speaker, including those ranges in which dual, in plane, drivers tend to acoustically interfere with each other.

Abstract: Compositions and methods for the treatment of sleep related breathing disorders are provided. Compositions include mirtazapine in combination with other active pharmaceutical ingredients, such as zonisamide, topiramate or modafinil. The treated sleep related breathing disorders include sleep apnea and sleep hypopnea. In some embodiments, the pharmaceutical compounds are used as adjuvant therapy with positive airway pressure (PAP) therapy, thereby lowering the pressure required to maintain airway patency during PAP therapy.

Abstract: Compositions and methods for the treatment of sleep related breathing disorders are provided. Compositions include setiptiline in combination with other active pharmaceutical ingredients, such as zonisamide, topiramate or modafinil. The treated sleep related breathing disorders include sleep apnea and sleep hypopnea. In some embodiments, the pharmaceutical compounds are used as adjuvant therapy with positive airway pressure (PAP) therapy, thereby lowering the pressure required to maintain airway patency during PAP therapy.